Economic Burden and Healthcare Resource Utilization of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Germany: A Claims Data Analysis
Author(s)
Yestle Kim, MSc, PharmD1, Thomas Ramezani, Dr.1, Christopher Maas, MSc2, Peter Rydqvist, PharmD1, Melinda Jo Daumont, MA, PhD1, John O'Donnell, MPP, PhD1, Jörn M Schattenberg, MD3, Frank Tacke, MD4.
1Madrigal Pharmaceuticals, West Conshohocken, PA, USA, 2Cencora, Hannover, Germany, 3Saarland University Hospital, Homburg, Germany, 4Charité - Universitätsmedizin Berlin, Berlin, Germany.
1Madrigal Pharmaceuticals, West Conshohocken, PA, USA, 2Cencora, Hannover, Germany, 3Saarland University Hospital, Homburg, Germany, 4Charité - Universitätsmedizin Berlin, Berlin, Germany.
OBJECTIVES: Metabolic Dysfunction-Associated Steatohepatitis (MASH) represents a significant health concern that imposes considerable economic burdens on the healthcare system. Given the rising prevalence of MASH in Germany, it is crucial to understand the associated healthcare resource utilization (HCRU) and costs. The aim of this study was to generate insights regarding the economic burden of MASH in Germany.
METHODS: A retrospective data analysis was performed using statutory health insurance claims data from 2017 to 2023 of the InGef research database. Patients were identified by ICD-10-GM diagnosis code K75.8 (MASH) in 2018 to 2022, by requiring ≥1 diagnosis during an inpatient encounter or ≥2 diagnoses codes in the outpatient setting. The first observable MASH diagnosis marked the index quarter. Exclusion diagnoses and presence of end-stage liver disease (ESLD) were considered in a 1-year baseline period prior to the index quarter. Outcomes were analysed in the follow-up period of the index quarter and all subsequent quarters within the study timeframe. Costs and HCRU related to MASH were assessed for patients with progression (P) and without progression (NP) during follow-up.
RESULTS: The analysis identified a total of 5,060 patients with MASH. Among these, 1,099 (21.7%) patients presented with ESLD at baseline and a total of 2,023 (40.0%) presented with progression (P-cohort).
The average cost per patient per year (PPPY) for the P-cohort was €13,070.89 compared to €4,981.86 in the NP-cohort. MASH/ESLD-related cost PPPY were also higher for progressed patients with €2,286.13 compared to €400.82 in the NP-cohort. Patients with progression experienced 1.76 hospitalizations PPPY, higher than for the NP-cohort with 0.96 hospitalizations.
CONCLUSIONS: The findings of this study highlight the economic burden associated with MASH in Germany, with patients progressing to ESLD incurring substantially higher costs. Targeted interventions aimed at preventing disease progression are required to mitigate its impact on patients and the healthcare system.
METHODS: A retrospective data analysis was performed using statutory health insurance claims data from 2017 to 2023 of the InGef research database. Patients were identified by ICD-10-GM diagnosis code K75.8 (MASH) in 2018 to 2022, by requiring ≥1 diagnosis during an inpatient encounter or ≥2 diagnoses codes in the outpatient setting. The first observable MASH diagnosis marked the index quarter. Exclusion diagnoses and presence of end-stage liver disease (ESLD) were considered in a 1-year baseline period prior to the index quarter. Outcomes were analysed in the follow-up period of the index quarter and all subsequent quarters within the study timeframe. Costs and HCRU related to MASH were assessed for patients with progression (P) and without progression (NP) during follow-up.
RESULTS: The analysis identified a total of 5,060 patients with MASH. Among these, 1,099 (21.7%) patients presented with ESLD at baseline and a total of 2,023 (40.0%) presented with progression (P-cohort).
The average cost per patient per year (PPPY) for the P-cohort was €13,070.89 compared to €4,981.86 in the NP-cohort. MASH/ESLD-related cost PPPY were also higher for progressed patients with €2,286.13 compared to €400.82 in the NP-cohort. Patients with progression experienced 1.76 hospitalizations PPPY, higher than for the NP-cohort with 0.96 hospitalizations.
CONCLUSIONS: The findings of this study highlight the economic burden associated with MASH in Germany, with patients progressing to ESLD incurring substantially higher costs. Targeted interventions aimed at preventing disease progression are required to mitigate its impact on patients and the healthcare system.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
HSD38
Topic
Health Service Delivery & Process of Care
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity)